| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	 
																	William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...
 
																	HC Wainwright & Co. analyst Emily Bodnar assumes TG Therapeutics (NASDAQ:TGTX) with a Buy rating and announces Price Tar...
 
																	
 
																	During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring e...
 
																	B. Riley Securities analyst Mayank Mamtani maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target fr...
 
																	 
																	